Medical Training In South Africa

12 December 1994

If the high standards of medical training in South Africa are to be maintained, the current training should be urgently reviewed and the capacity expanded significantly, according to Erik Glatthaar of the Faculty of Medicine of the University of Pretoria.

Prof Glatthaar conducted a study on the need for physicians and medical schools in South Africa and concluded that "the closure of any of the existing (seven) medical schools without intensive further investigations will have disastrous long-term implications, and not be in national interest at all."

The research follows on a current debate regarding the rationalization/closure of certain medical schools in South Africa. The report has been made available to the committees appointed by the country's Health Minister to investigate human health resources and academic matters.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight